Nelson N. Stone, MD, presented “Long-term Morbidity of ADT and Radiation Therapy” during the 24th Annual Southwest Prostate Cancer Symposium on April 14, 2019 in Scottsdale, Arizona.

How to cite: Stone, Nelson N. “Long-term Morbidity of ADT and Radiation Therapy” April 14, 2019. Accessed Dec 2023.

Long-term Morbidity of ADT and Radiation Therapy – Summary:

Nelson N. Stone, MD, discusses long-term data about extended neoadjuvant hormone therapy following radiation therapy for high-risk prostate cancer patients. He observes the morbidity, mortality, and testosterone recovery rates of extended hormone therapy, especially in patients treated with hormone therapy for over 6 months.


Until recently, there has been a lack of data with long-term follow-up to provide a consensus regarding the benefits and/or risks of extended neoadjuvant hormone therapy for prostate cancer patients previously treated with radiation. While research has shown that hormone therapy may have some negative effects, there is no clear pathway as to how physicians should respond to these findings.

For example, one study indicated that patients treated with 3 years of hormone therapy have a harder time regaining pre-castrate levels of testosterone than patients treated with 6 months of therapy. This could mean that patients who have other risk factors that may make it difficult to regain testosterone, such as high body-mass index and low baseline testosterone, should not receive hormone therapy for as long.

There has been much investigation into the negative effect of hormone therapy on cardiovascular health, though findings have been too inconsistent to reach any conclusions. Another study found that hormone therapy could increase patients’ risk for all-round mortality, but only if they were 73 or older. This could suggest that clinicians should only consider younger patients for neoadjuvant hormone therapy.

Recently reported long-term outcomes put these prior findings into context. 15-year data suggests greater mortality in prostate cancer patients who had more than 6 months of hormonal therapy versus patients who had none. A large, long-term study investigating the influence of neoadjuvant hormone therapy and testosterone levels on all cause survival, controlling for other coexisting medical conditions, found that patients lose approximately 2 years of life by undergoing over 6 months of neoadjuvant hormone therapy.

Considering that researchers have never been able to show that hormonal therapy has a benefit in patients treated with high-dose radiation, this new research may prompt the urology community to reconsider how it uses this method.          

About the Southwest Prostate Cancer Symposium

The Southwest Prostate Cancer Symposium (SPCS) is a multi-day conference that seeks to educate urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. The topics focus on current technical aspects of diagnosis and treatment of localized and advanced disease, particularly regarding imaging, technology, and training in the related devices. Dr. Stone presented this lecture during the 24th SPCS in 2019. In 2020, the 25th SPCS will also offer training sessions involving imaging, scanning, and prostate cancer treatment related devices on site. Please visit this page in order to register for future SPCS meetings.